The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension

@inproceedings{Busch2006TheAG,
  title={The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension},
  author={Martin Busch and Sybille Franke and Gunter Wolf and Antje Brandst{\"a}dt and Undine Ott and Jens Gerth and Lawrence G. Hunsicker and Guenter Stein},
  year={2006}
}
Background: Advanced glycation end products (AGEs) are implicated in the pathogenesis of vascular damage, especially in patients with diabetes and renal insufficiency. The oxidatively formed AGE N e -carboxymethyllysine (CML) is thought to be a marker of oxidative stress. Methods: Four hundred fifty patients with type 2 diabetes and nephropathy from the Irbesartan in Diabetic Nephropathy Trial cohort (mean age, 58 ± 8.2 years; 137 women, 313 men) with a mean glomerular filtration rate of 48.2… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.

  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2008
VIEW 3 EXCERPTS
CITES METHODS & BACKGROUND

Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women.

  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2009
VIEW 1 EXCERPT
CITES RESULTS